J&J Golimumab BLA Filing Planned For First Half 2008 In Three Indications
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's Centocor unit is on track to file a BLA for the next generation tumor necrosis factor inhibitor golimumab in the first half of 2008. The company plans to file the biologic simultaneously in three indications: rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis